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Background 
Early diagnosis of symptomatic cancer is considered to be central to the achievement of better 
outcomes.1 There are national initiatives in many countries with the intention of achieving earlier 
presentation with symptoms, and earlier diagnosis through more effective diagnostic routes. For 
example, the English National Awareness and Early Diagnosis Initiative (NAEDI)1 is a programme 
of work intended to achieve earlier presentation of people with symptoms, to optimise clinical 
practice and to improve GP access to diagnostics.  Similar important initiatives are being 
undertaken in a growing number of jurisdictions.2 
 
Variations in cancer survival between countries of comparable affluence and health systems have 
prompted international efforts to better understand these differences, often with a focus on the 
role of earlier diagnosis.3  The scope for interventions to improve early diagnosis is wide, and is 
receiving significant investment by national governments.  Several of these have acknowledged 
the need for complementary programmes of research in order to gain better understanding of 
patient and clinician behaviour and to determine the effectiveness of the interventions they are 
funding.4,5 
 
Research in this area is, however, complex; pathways to cancer diagnosis are often not 
straightforward and rarely linear.6,7 The health system context in which research is carried out has 
a major influence on individual stages of these pathways. Moreover, the published research to 
date is characterised by a wide range of methodological approaches, often poorly or imprecisely 
described and with little theoretical basis.  A wide range of methods have been used to measure 
time points and intervals, often dictated by the available data and resources.8 As a result, 
research findings are frequently difficult to interpret and typically not comparable beyond 
individual countries.  
 
Furthermore, a number of different theoretical and methodological perspectives have been 
applied to the definition and measurement of time points and intervals in early diagnosis research, 
and these perspectives are often not explicitly delineated in the literature to date. Biomedical 
approaches predominate - they imply a direct relationship between disease and symptoms in the 
presence of illness. Other perspectives are less well-integrated within the literature; psychological 
approaches distinguish between ‘bodily changes’ (both sensations and visible changes) and 
‘symptoms’ and are interested in the processes by which one becomes the other.9,10,11  
Sociological and anthropological approaches explore the processes by which bodily sensations 
are interpreted as symptoms; they are predicated on the view that symptoms evolve and are 
interpreted through the relationship between the individual and a given social and cultural 
context12.  
 
In the light of different purposes of the research, several theoretical models have been developed 
to describe the events and processes that underpin the pathway to symptomatic cancer 
diagnosis.  Influential among these is the Danish model developed by Olesen and colleagues4 
and the Model of Pathways to Treatment (see Figure 1), a refinement by Walter and colleagues of 
the Andersen Model of Total Patient Delay.13 
 
INSERT FIGURE 1 ABOUT HERE 
 
Hence, early diagnosis research is characterised by its complexity, a poorly developed set of 
definitions and methodological tools, a lack of transparency in disciplinary perspectives and an 
absence of a widely-accepted underlying theoretical model. Accordingly, in order to advance the 
quality and consistency of studies of diagnostic intervals in symptomatic cancer, an international 
Consensus Working Group (CWG) was convened in November 2009. The purpose of the group 
was to formulate definitions of key time points and to make methodological recommendations for 
researchers in this field. The work was commissioned by Cancer Research UK and the 
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Department of Health in England, and undertaken under the auspices of the Cancer and Primary 
Care Research International (Ca-PRI) Network.14    
 
The aim of this paper is to propose and discuss a standardised set of definitions that can be used 
in research on earlier cancer diagnosis, relating to key timepoints and intervals in early diagnosis 
research. We also present methodological recommendations, principally on data collection and 
analysis.  
 
 
Methods 
We used a ‘consensus conference’ approach15 which encompasses consensus meetings, 
presentations and wide circulation of draft outputs for modifications and refinement. It has been 
used in other fields to produce guidance for researchers and clinicians, and is particularly useful 
when a wide range of clinical, sociological, cultural and other perspectives need to be 
incorporated within the guidance. We also drew on nominal group techniques16 in our consensus 
meetings and in the exchange of information in the intervals between the meetings. 
Members of the CWG were drawn from a range of disciplinary and methodological backgrounds 
including primary care, health services research, social science, psychology, epidemiology and 
statistics.  The CWG was supported by an international expert reference group comprising 
individuals from a wide range of clinical and methodological backgrounds. The CWG met three 
times between January and November 2010 in London and Aarhus. Each of the meetings 
comprised a series of presentations addressing theoretical, empirical and research 
methodological key areas of the project; the ensuing discussions were recorded and circulated 
between meetings. Consensus was achieved through an iterative approach whereby proposed 
statements and checklists were developed and refined in the course of these meetings and 
informed by the presentations.  Each element of the statement was discussed in detail by all 
members of the group until consensus was reached. The draft statement was then reviewed by 
an expert reference group and further refined in the light of their feedback.  
The CWG had a close familiarity with the literature in this field. Nevertheless, we decided to 
underpin this by using systematic approaches to identify and assess relevant literature relating to 
existing questionnaires and survey tools. Accordingly, we further examined 279 included papers 
from a concurrent systematic review examining the association between outcomes and diagnostic 
intervals17. The inclusion criteria are shown in Box 1.  
 
 
 
INSERT BOX 1 ABOUT HERE 
 
 
Results 
After examining the early cancer diagnosis literature, and taking into account the extensive 
theoretical work in this field, the CWG concluded that: 
 
 there is little consistency in the definition and measurement of key time-points and intervals;  
 there is little guidance for researchers in designing studies which require the measurement of 
diagnostic time-points and intervals; 
 little work in this field explicitly uses a theoretical framework to underpin definitions and 
measurement of diagnostic intervals; 
 there is a lack of transparency and precision over methods and instruments in early diagnosis 
research – typically, important study elements such as instrument development are poorly 
described. 
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Accordingly, the CWG group developed the ‘Aarhus Statement’ comprising the following series of 
definitions and recommendations: 
 
1. Definitions 
The relevance of individual time-points and intervals varies between health care systems. 
Nevertheless, in an international context, the importance of the following four time-points emerged 
in the Consensus Working Group discussions – we found the representation in Figure 2, 
illustrating the time-points and their associated intervals, helpful: 
 
INSERT FIGURE 2 ABOUT HERE 
 
Date of first symptom 
This should be defined as ‘the ‘time-point when first bodily change(s) and/or symptom(s) are 
noticed’. Researchers should consider this definition to encompass several key components: the 
date the first bodily change was noticed, the date the first symptom was noticed, the date when 
the person perceives a reason to discuss the symptom with a health care professional, and the 
date the first ‘alarm’ or ‘higher risk’ symptom was noticed. Researchers should report clearly 
which of these definitions of first symptom has been applied in their study.  
 
The term ‘patient delay’ should no longer be used - instead, ‘appraisal interval’ (time taken to 
interpret bodily changes/symptoms) and ‘help-seeking interval’ (time taken to act upon those 
interpretations and seek help) are more helpful in describing the ‘patient interval’ (see Figure 1). 
Researchers should acknowledge in their definition how they have dealt with the complexity of 
this time-point, for example, where symptoms are common, non-specific, multiple or chronic, 
where other morbidities co-exist, and the social and healthcare context.  It is important to 
recognise that often symptoms are medically defined, and such definitions may  be inconsistent 
with lay symptom definitions. 
 
Date of first presentation 
This should be considered ‘the time-point at which, given the presenting signs, symptoms, history 
and other risk factors, it would be at least possible for the clinician seeing the patient to have 
started investigation or referral for possible important pathology, including cancer’. There should 
be a demonstrated understanding of the pattern of symptoms in the lead up to the first 
presentation (eg frequency, chronicity, presence of other symptoms), and whether the date has 
been defined from the perspective of the health care provider or the patient. There should be 
precise descriptions of where this first presentation occurs (eg primary care, hospital department 
etc). 
 
Date of referral 
This should be considered ‘the time-point at which there is a transfer of responsibility from one 
health care provider to another (typically, in ‘gatekeeper’ health care systems, from a primary care 
provider to a doctor/service specialising in cancer diagnosis and management) for further clinical 
diagnostic and management activity relating to the patient’s suspected cancer’. Patients may be 
referred more than once or between specialists; there are risks of cross-referrals within secondary 
care, and complex diagnostic routes (where patients ultimately receive treatment from specialist 
services which are different to those initially targeted). Researchers should use a consistent and 
explicit method for dealing with such complexities. Further, referral for investigations should be 
considered as a subsidiary time-point that may be of significance in some health care settings, but 
is not equivalent in cases where actual responsibility for patient management is not transferred. 
The service targeted in the referral should also be described. 
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Date of diagnosis 
Studies reporting any time interval that either begins or ends with ‘diagnosis’ should be explicit 
about how that date is measured and what it actually means with respect to the diagnostic journey 
within that health system. Researchers should consult the well-developed hierarchical rationales 
available in the public domain in choosing their definition of date of diagnosis – one example is 
the hierarchy produced by the European Network of Cancer Registries18 which is shown in Box 2. 
 
INSERT BOX 2 ABOUT HERE 
 
2. Methodological Approaches 
 
Most studies on early cancer diagnosis involve retrospective data collection, which can be subject 
to recall bias.19 Prospective studies on patients with symptoms are often recommended20, 
although they pose difficulties due to the large numbers of participants required. Time since 
diagnosis is a critical sampling issue - sampling too long after diagnosis increases the risk of 
recall bias and increases the likelihood of attrition due to death or terminal illness. Conversely, 
sampling too soon after diagnosis may be insensitive, and may increase the likelihood of attrition 
due to ongoing active treatment (surgery, chemotherapy, radiotherapy). The sampling method, 
whether through a cancer registry, hospital-based sampling or other mechanism, should be 
reproducible and thoroughly described. 
 
Primary data collection from patients and/or providers 
The key challenge in collecting data on diagnostic intervals is to obtain valid and complete data 
and, at the same time, capture the complexity of the pathways to a diagnosis of cancer. However, 
this might lead to overly-cumbersome approaches and significant response burden. Therefore, 
researchers should develop questions which are 1) precise about the time-point they are 
endeavouring to describe, 2) applicable to both the cancer in question and the likely symptom and 
symptom complexes that the patient experiences, and 3) specific about the context of the health 
care system.  
 
Questions should derive from a clearly-stated theoretical basis, and the health care context 
should be clearly described, to allow for appropriate interpretation of responses. Ways in which 
the measurement approach takes into account multiple symptoms, chronic symptoms and co-
existent co-morbidity should be described. 
 
For measurement of the date of first symptom and date of first presentation, in-depth qualitative 
interviews with patients are preferred when there is a need for detailed understanding of the time-
point. Strategies such as calendar-landmarking21 should be considered to reduce recall bias in 
qualitative interviews. In common with research in other fields, patient-completed surveys 
(typically in the form of self-completion questionnaires) provide the best opportunity for producing 
large, population-based data-sets, but their limitations in capturing the complexity of these time-
points should be acknowledged and researchers should clarify how the survey has been 
developed in accordance with international standards.22 
 
For date of first presentation, ideally information should be gathered from both patients and 
primary care providers, as their concepts of this time-point may differ, particularly in the context of 
vague, non-specific or chronic symptoms. Open-ended questions, while making coding more 
difficult, are typically needed to encompass the complexity of cancer-related symptoms when 
asking patients. 
 
It is important to scrutinise the literature to be sure that projects include the best available 
measurement instrument. In future we might see internationally validated standard questionnaires 
in this field. Therefore, it is also important that researchers provide very transparent information 
on development of interviews and surveys. 
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Case-note audit 
Retrospective examination of case-notes (eg charts, medical records) is an important source of 
information in medical research and clinical audit; a vital consideration is the accuracy of this 
information.23 This approach should ideally be used to augment or validate data from other 
sources – particularly for complex time-points such as date of first symptom. There should be a 
description of the process of how the clinician makes and codes the record, and how clinicians 
interpret and record the patient’s history in the clinical notes. Further, the likely completeness of 
the case-note data should be described. There is typically little data in secondary care notes on 
early stages of diagnostic pathways (ie time-points before the patient arrives in secondary care), 
although they are an important source of information on latter stages of the patient journey. 
 
Primary care database analysis 
There has been a growth in the number and quality of databases which collect encounter and 
diagnostic information from primary care – one example is the General Practice Research 
Database (GPRD).24 These offer the potential to conduct analyses on large samples, and can 
facilitate study designs such as retrospective cohort studies. When used, there should be a 
thorough description of the database and its capacity to capture valid information on time-points 
and intervals (eg completeness and accuracy of recording of encounter data). Further, the 
limitations deriving from coding systems used in the database should be described and there 
should be standard procedures for both conceptualising data fields and uploading data in a 
standard format. In common with case-note audit, there are limitations in deriving information on 
time-points such as date of first symptom from analysis of databases – although both audit and 
database analysis can be useful in deriving information on date of first presentation. 
 
 
3. The Aarhus Check-list 
Based on these recommendations, the CWG has developed a check-list for early diagnosis 
researchers. The check-list is intended for individuals undertaking research which involves the 
description and measurement of intervals in the cancer diagnostic journey.  It has been produced 
with the intention of promoting greater consistency and transparency in methods and 
measurement.  Furthermore, it is a resource both for those developing studies which require 
measurement of intervals and/or mapping of cancer patient journeys, and for journal paper 
reviewers, editors and funding bodies who can use these items as a framework for assessing the 
quality of research applications and papers. 
 
INSERT AARHUS CHECK-LIST ABOUT HERE 
 
 
Discussion 
We report the first comprehensive guidance for the conduct and reporting of research in this field. 
We have highlighted the many needs and pitfalls in early diagnosis research, and call for greater 
precision and transparency in both definitions and methods. Our rigorous and multidisciplinary 
approach to consensus development, coupled with detailed analysis of the existing early 
diagnosis literature, has produced guidance which can promote [the primary] consistency and 
methodological rigour in this field. Our recommendations are relevant to researchers, funding 
bodies, and journal editors and reviewers. The next step is to examine whether these definitions 
and recommendations can be readily adopted by researchers; evidence from similar previous 
initiatives suggests that researchers are receptive to new methodological guidance, and that it can 
have a positive effect on research quality25, 26.  
 
While our check-list has not addressed analytical techniques, the choice of technique is crucial 
given that analyses of time intervals are used to monitor quality of clinical trajectories and in 
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research on prognosis of cancer. In prognostic research there is strong evidence to suggest that 
time interval data should be analysed in a statistical model using time interval as a continuous 
variable, rather than a dichotomized model, in order to minimise bias arising from what has been 
termed ‘the waiting time paradox’.27,28 
 
We have identified a pressing need for more methodological work in this field and we are in the 
process of further evaluation and validation of our recommendations, which can be viewed in 
greater detail on the Ca-PRI website.14  Feedback on the guidance will be used for future updates.  
 
 
 
Conclusions 
There are growing international efforts to describe and measure patient journeys prior to a cancer 
diagnosis.  Accurate descriptions of these patient journeys and valid measurements of diagnostic 
intervals are essential to determine the effectiveness of interventions to reduce them.  The Aarhus 
Check-list will facilitate standardised and uniform definition and reporting of studies in this area. 
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Box 1: Inclusion criteria for systematic review 
 
A study or analysis was included in the review if it fulfilled all the criteria below: 
- Participants: only studies or analysis that examined symptomatic cancer patients 
presenting with primary cancers were included.  
- Aim of study: ideally, to analyse the impact of the interval between the time of first 
symptomatic presentation to definitive diagnosis or treatment on a health-related outcome.  
- Outcome: any study analysing any health-related outcome was considered for inclusion; 
these include survival, diagnostic stage, treatment assignment after diagnosis, and other 
measures of “curability”. Survival was the main outcome of interest; additionally, studies 
examining health-related quality-of-life, resource-use and psychological outcomes were 
considered for inclusion.  
- Study design: there were no restrictions on the types of study design that were considered 
for inclusion. 
 
 
 
 
Box 2 - European Network of Cancer Registries: Hierarchy for defining date of 
diagnosis18 
 
In order of declining priority….. 
1.  Date of first histological or cytological confirmation of this malignancy (with the exception 
of histology or cytology at autopsy). This date should be, in the following order:  
 a) date when the specimen was taken (biopsy)  
 b) date of receipt by the pathologist  
 c) date of the pathology report.  
2.  Date of admission to the hospital because of this malignancy.  
3.  When evaluated at an outpatient clinic only: date of first consultation at the outpatient 
clinic because of this malignancy.  
4.  Date of diagnosis, other than 1, 2 or 3.  
5.  Date of death, if no information is available other than the fact that the patient has died 
because of a malignancy.  
6.  Date of death, if the malignancy is discovered at autopsy.  
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Figure 1 - Model of Pathways to Treatment13 
 
 
 
 
 
Figure 2 - An illustration of the overall milestones and time intervals in the route from first 
symptom until start of treatment4  
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The Aarhus Check-list 
 
 
Item  Y/N 
DEFINITIONS OF TIME-POINTS AND INTERVALS 
 
1. For studies requiring the measurement of an interval, are the beginning and end 
points of this interval clearly defined? 
 
 
2. For all time-points and intervals described are there precise, transparent and 
repeatable definitions, and is the complexity of time-points such as date of first 
symptom and date of first presentation addressed? 
 
 
For studies which require an estimate of date of first symptom: 
 
3. Do the researchers refer to a theoretical framework underpinning definition of this 
time-point? 
 
 
4. Is there a discussion of the different biases influencing measurement of this time-
point 
 
 
For studies which require measurement of a date of first presentation to healthcare: 
 
5. Do the researchers discuss the complexity of the date of first presentation?  
 
 
For studies which require measurement of a date of referral: 
 
6. Do the researchers discuss the nature of the referral, and provide adequate detail 
– eg whether it was for investigation or consultation by a colleague in secondary 
care?  
 
 
For studies which require measurement of date of diagnosis: 
 
7. Do the researchers use an existing hierarchical rationale for date of diagnosis 
measurement? 
 
MEASUREMENT 
 
8. Is the healthcare context in which the study is based fully described? 
 
 
9. Do the questions on time-points and/or intervals clearly derive from stated 
definitions? 
 
 
10. Do researchers acknowledge the need for theoretical validation and make 
reference to the theoretical framework(s) underpinning measurement and analysis 
of the time-points? 
 
 
For studies using questionnaires and/or interviews with patients and/or healthcare providers: 
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11. Has a validated instrument been used? 
 
 
12. Have the researchers included a copy of their instrument? 
 
 
13. Is there some discussion of how reliability and validity (trustworthiness) has been 
established? 
 
 
14. Do researchers acknowledge the need for theoretical validation and make 
reference to the theoretical framework(s) underpinning measurement and analysis 
of the time-points? 
 
 
15. Is there discussion of the different biases influencing measurement of the time-
points, such as how and when the question is asked and who is being asked? 
 
 
16. Is the timing of the interview in relation to the date of diagnosis provided? 
 
 
17. Is there any triangulation of self-reported data with other data sources such as 
case notes? 
 
 
18. Is data analysis described in full including how and why data are categorised, how 
missing, and incomplete data are managed and how outliers at both ends of the 
spectrum are accounted for? 
 
 
For studies using primary case note audit and database analysis: 
 
19. Case-note analysis: is there a clear and precise description of how case note data 
were used to ascertain time-points with an acknowledgment of limitations of such 
data? 
 
 
20. For database analysis: is there a thorough description of the database chosen 
including sampling coverage and completeness of information? 
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